CAR T Toxicities in Focus: What We Have Learned from Registry Data
Shownotes
In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention.
Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy.
Guest:
Dr Annalisa Ruggeri
Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMT
Host: Leah DeLeon
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe